Drug intelligence / Profile preview

Chisan

Development stage
Unknown
Lead developer
Swedish Herbal Institute
Modality
Small Molecules
Administration
Oral
01

Overview

Chisan (also known as ADAPT-232) is a standardized herbal combination product containing extracts of three adaptogenic plants: *Rhodiola rosea* (Arctic root), *Schisandra chinensis* (Schisandra berry), and *Eleutherococcus senticosus* (Siberian ginseng). Developed and marketed by Circius Pharma, it is used as an adaptogen to alleviate symptoms of fatigue, tiredness, and weakness, and to improve physical performance. The active components work synergistically to modulate the stress response and provide protective effects against physical and mental stressors. While primarily marketed as a traditional herbal medicine or dietary supplement for over-the-counter use, it has been investigated in clinical trials as an adjuvant therapy for acute non-specific pneumonia and Long COVID symptoms, showing potential benefits in improving quality of life and reducing recovery time.

Brand names
Chisan
Other names
ADAPT-232ADAPT232ADAPT 232
02

Targets

HSPA1A (HSP70-1A)NPYR (Neuropeptide Y receptors)

Beyond the preview

Go deeper on Chisan.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Chisan.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call